Brainomix Raises £14M to Expand AI Imaging for Stroke and Lung Care

Strategic investment to scale clinical AI tools

Brainomix, a UK-based medical technology company specializing in AI-powered imaging solutions, has raised £14 million (approximately $18 million) in Series C funding to accelerate its expansion in the fields of stroke and lung fibrosis diagnostics. The new investment increases the company’s total funding to £44 million ($57 million), reinforcing its position as a key player in the integration of AI within medical imaging.

The round was co-led by Parkwalk Advisors, the UK’s largest growth EIS fund manager, and the Boehringer Ingelheim Venture Fund (BIVF). They were joined by Hostplus, an Australian industry superannuation fund managing over AUD$120 billion, through the IP Group Hostplus Innovation Fund, alongside LifeSci Capital. The new capital will support further technological development and the clinical validation of Brainomix’s AI platforms, strengthening their reliability and global adoption.

Transforming stroke diagnosis with automation

One of Brainomix’s flagship products, Brainomix 360 Stroke, offers automated interpretation of brain scans to support timely and informed decision-making for stroke patients. The software is designed to function even in hospitals with limited access to stroke specialists, allowing clinicians to assess imaging results more efficiently. Use of the technology has been associated with a 50% increase in the number of patients receiving mechanical thrombectomy, a crucial intervention that improves post-stroke outcomes.

Brainomix was founded by Dr. Michalis Papadakis and Professor Alastair Buchan at the University of Oxford. Dr. Papadakis, who serves as CEO, previously led Oxford’s preclinical stroke research lab, while Professor Buchan developed ASPECTS, a globally recognized scoring method for CT scan evaluation in stroke cases. Their combined scientific expertise laid the foundation for Brainomix’s innovations in diagnostic imaging.

Broadening scope to respiratory disease and US market

Beyond neurology, Brainomix has extended its reach into respiratory care with Brainomix 360 e-Lung, a tool developed to forecast disease progression in patients with lung fibrosis. The platform recently received FDA clearance and is being evaluated through a collaboration with Boehringer Ingelheim, a pharmaceutical leader in interstitial lung disease treatment. The goal is to validate the technology in real-world clinical settings and improve early identification of patients who could benefit from targeted therapies.

With ten FDA approvals secured to date, Brainomix is preparing to increase its footprint in the United States. The company, which currently employs over 75 people, plans to expand its workforce in Oxford and build out its international commercial team. Recruitment efforts will focus on AI development, regulatory affairs, and business development to support global scaling efforts.

Positioning in a competitive landscape

In the rapidly evolving AI imaging sector, Brainomix faces competition from US-based firms such as RapidAI and Viz.ai. However, Brainomix holds a leading position in Europe, where its solutions have been widely deployed, including across Hungary, Wales, and most English stroke units. This level of adoption has helped establish Brainomix’s credibility and positions the company to extend its AI applications to other medical domains where complex imaging interpretation poses barriers to care.